Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Phosphatase and tensin homolog (PTEN) mRNA 3' untranslated region (3'UTR) is a critical regulatory segment of the PTEN transcript that governs the protein's expression levels through post-transcriptional mechanisms (Tay et al., 2011, Nature). PTEN is a major tumor suppressor that inhibits the PI3K/AKT/mTOR pathway, and its downregulation is a hallmark of various cancers, including prostate, breast, and glioblastoma (Worby and Dixon, 2014, Nature Reviews Molecular Cell Biology). The 3'UTR is exceptionally long and contains numerous binding sites for microRNAs, such as miR-21, miR-19, and miR-214, which bind to the region to suppress translation or induce mRNA decay (Poliseno et al., 2010, Nature). Because PTEN is often haploinsufficient, meaning the loss of even one allele or a reduction in expression can promote tumorigenesis, therapeutic strategies aim to increase its expression by targeting the 3'UTR. This is achieved using antisense oligonucleotides (ASOs) or target site blockers (TSBs) that sterically hinder miRNA binding, effectively de-repressing PTEN and restoring its tumor-suppressive activity (Matsui and Corey, 2017, Chemical Reviews). These RNA-targeted therapies represent a precision medicine approach to treating malignancies where PTEN expression is attenuated but the gene remains functionally intact.
Steric hindrance of microRNA binding sites (e.g., miR-21, miR-19) within the 3'UTR to prevent translational repression and mRNA degradation, thereby increasing PTEN protein levels and restoring tumor-suppressive activity (Matsui and Corey, 2017).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatase and tensin homolog mRNA 3' untranslated region (PTEN mRNA 3'UTR).